Rohit Loomba
@DrLoomba
Followers
7K
Following
16K
Media
349
Statuses
4K
Liver doctor/Professor of Medicine/clinical trial design Phase 1-4/inventor/drug developer/life's goal to find a cure for liver fibrosis & NASH.
San Diego, California
Joined December 2011
We are so proud of your contributions @MonicaTincopa !
Honored to be supported by @AmCollegeGastro for our important work towards #HealthEquity for the #Hispanic #Latino community with chronic #liver disease @MASLDResearch @DrLoomba @UCSDHealth
0
1
12
Looking forward to new collaborations @APASLnews - across the spectrum of SLD @shivsarin @l_suthat @japantimes @MASLDResearch @DrHuangDQ
2
3
38
International collaborative review on Clinical trial design, biomarkers & endpoints in MetALD https://t.co/rhdbR06YmJ
@AASLDtweets @EASLnews @MASLDResearch @AmCollegeGastro @INASL_Liver @APASLnews
1
15
47
Any final year GI fellow with training/concentration in IBD or GI motility or IBS or Pancreas or AI interested in a faculty job in sunny San Diego @UCSD_GI please dm would love to explore possibilities with you & create an ideal position @AmerGastroAssn @AmCollegeGastro
0
3
25
If you are an APP and interested in working at the top of your license with experience in General GI, IBD or motility please reach out to me- pl consider joining our GI team @UCSD_GI - we greatly value and celebrate our GI & liver APP team! @AmerGastroAssn @AmCollegeGastro
0
0
2
Please join us for the exciting liver symposium on November 6th, Washington DC https://t.co/COMcAL6ONl -- Great group of speakers & cutting-edge topics including regulatory path for NIT drug development in MASH & cirrhosis! @EASLnews @QAnstee @AlkhouriNaim @precisionliver
precisionliversymposium.org
The Second Annual Thursday Liver Symposium: Dawn of a New Era in Precision Medicine: Genetics and Biomarkers in Liver Disease and Cirrhosis, will take place on Thursday, November 6, 2025, in Washin...
0
5
21
Using NIT to assess semaglutide response using Phase 2b data- check it out!
Read open access via https://t.co/J37ZBiPwWt "Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH" #livertwitter #MASH #semaglutide #NITs
1
7
18
We invite you to join our collaborative team @UCSD_GI @UCSDHealth
apol-recruit.ucsd.edu
University of California, San Diego is hiring. Apply now!
0
1
5
Join us for an insightful session chaired by Michael Wallace and Ericka Flores, exploring cutting-edge approaches to Hepatocellular Carcinoma (HCC) prevention, surveillance, and treatment. Explore the WCOG@AGW25 program: https://t.co/2CkWLd76bw
0
5
8
#Throwback COMMENT | C Hsu & @DrLoomba From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research https://t.co/ofcR1MXM60
nature.com
Nature Metabolism - Non-alcoholic liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver disease (MASLD), emphasizing the key metabolic factors of obesity, insulin...
0
4
9
Roche to acquire liver drug developer 89bio for up to $3.5 billion | Reuters-
reuters.com
Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight-loss drugs.
0
0
5
🌟Celebrate Hispanic Heritage Month with our new member network La LiGaH! Join @MonicaTincopa, @SandraQuezadaMD, Dr. Hugo Vargas & Dr. Silvio de Melo to explore health disparities & health equity concerns in GI and hepatology for the Latino community. 🔗 https://t.co/QzzLCmRYzZ
0
0
5
Kudos to @MadamSurgeonMD to organize such a trailblazing symposium @UCSDHealth @UCSDCancer - great panel on early detection of colon cancer led by @samirguptaGI Ludmil Alexendrov !!! @UCSD_GI @AmbryGenetics
0
1
7
Grateful to have such an amazing international organizing committee!!!
Learn from the experts at the Second Annual Thursday Liver Symposium! Cutting-edge updates, practical strategies, and leading voices in liver care—all in one event. Register now: https://t.co/g8ORkSWwLP
0
3
25
Don’t miss this session at the Thursday Liver Sympo! 📢 Guadalupe Garcia-Tsao, MD, FRCP will break down the key NEJM papers on SLD and cirrhosis, highlighting the latest evidence and what it means for patient care. 👉 Seats are limited—register now at https://t.co/g8ORkSWwLP
1
1
2
Learn from the experts at the Second Annual Thursday Liver Symposium! Cutting-edge updates, practical strategies, and leading voices in liver care—all in one event. Register now: https://t.co/g8ORkSWwLP
0
11
19
Such a great pleasure to have @SeragHashem at @UCSD_GI for our flagship Isenberg Lectureship! Learned a lot about HCC biomarkers and learning health system! An amazing treat for our faculty and trainees - true joys of academic medicine! @AmerGastroAssn
1
6
46
Delighted to report our new paper on DGAT-2 silencing in MASH- Antisense oligonucleotide DGAT-2 inhibitor, ION224, for MASH (ION224-CS2): results of a RCT, phase 2b trial - The Lancet https://t.co/fN3CDePkLl
@AlkhouriNaim @MASLDResearch @CALonghurst
5
21
73
Fabulous work @CristiLlorente !!! We are all @UCSD_GI so proud of you and your accomplishments!!!
✨Our work shows that mAChR4-regulated goblet cell–associated antigen passages (GAPs) act as sentinels of gut immunity in alcohol-associated liver disease (ALD). These findings identify mAChR4 and IL6ST agonists as promising therapeutic options in ALD.📷 https://t.co/PQGFlhb75g
1
1
13